Topiramate, zonisamide and small for gestational age: maternal factors, timing of exposure and baby fat by Harden, C. L.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2014
Topiramate, zonisamide and small for gestational
age: maternal factors, timing of exposure and baby
fat
C. L. Harden
Hofstra Northwell School of Medicine
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Neurology Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.
Recommended Citation
Harden CL. Topiramate, zonisamide and small for gestational age: maternal factors, timing of exposure and baby fat. . 2014 Jan 01;
14(4):Article 1310 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/1310. Free full text article.
199
Epilepsy Currents, Vol. 14, No. 4 (July/August) 2014 pp. 199–200 
© American Epilepsy Society
Current Literature
In Basic Science
Commentary
Small for gestational age (SGA) is commonly defined as weight 
below the 10th percentile for gestational age (1). The concern 
regarding SGA is its implications for development; it is associ-
ated with an increased risk for neonatal distress, permanent 
deficits in growth and neurocognitive development, and 
mortality. However, SGA babies are a heterogeneous group, 
and approximately 50% are constitutionally small, due to ma-
ternal ethnicity, body habitus, and body mass index (BMI) and 
these infants will develop normally (2). In 2005, 10% of births 
to Hispanic, American Indian/Alaska Native, and non-Hispanic 
white women in the United States met the criteria for SGA, and 
the occurrence in non-Hispanic Black births was 17% (1).
Topiramate is associated with an increased risk of ma-
jor congenital malformations (MCMs), with 1.4 % of births 
showing facial clefts, recently described by this group (3, 
4) and others (5). These rare cases were excluded from the 
analysis herein. Within the North American Antiepileptic Drug 
Pregnancy Registry (NAAEDPR), a structurally related drug, 
zonisamide has been associated with a low risk of MCMs, with 
none occurring in 90 monotherapy exposures, therefore the 
upper limit of the 95% confidence interval (CI) is 3.3% (3). 
The authors adjusted for many factors that could contrib-
ute to small for gestational age, including smoking, maternal 
illness, and socioeconomic indicators. The overwhelming 
majority of mothers were Caucasian (> 85%) which minimizes 
the ethnic variability that could result in some SGA babies. This 
was also very highly educated cohort. Having at least 2 years 
of college education was reported in 45% of the topiramate-
treated mothers, and this was the least educated group. 
The investigators also evaluated factors that would not be 
predicted to associate with SGA, but need to be looked at just 
the same, such as the indication for use including migraine 
and epilepsy. They found no association by indication. Overall, 
this appears to be a group with low risk for ethnic or socioeco-
nomic influences on the occurrence of SGA. Therefore these 
rates may be underestimates for other populations. 
An epilepsy-related factor that associates with SGA is the 
occurrence of seizures during pregnancy (6). This was evalu-
ated and showed no association. 
Another epilepsy-related factor associated with SGA is 
AED polytherapy (7). The authors evaluated a group exposed 
to lamotrigine plus other AEDs and found an SGA propor-
tion of 10%, lower than that with topiramate or zonisamide 
polytherapy. Polytherapy exposures, although incompletely 
described in this report and not discussed as independent 
groups, showed a trend toward an adverse effect. From the 
spectrum of AED associations with SGA, TPM as monotherapy 
or polytherapy carried the most risk. 
The question as to the underlying mechanism of topira-
mate-associated SGA is paramount. Weight loss surely does 
occur with these AEDs, and TPM is now marketed as part of a 
combination pharmaceutical agent having an indication for 
the treatment of severe obesity (8). An obvious limitation of 
this study is that maternal weight and maternal weight change 
during pregnancy were not adjusted for in this analysis, since 
they are associated with either SGA or LGA (large for gesta-
tional age) (9). It was stated, however, that the data was not 
available for such. 
Topiramate’s mechanism of action in producing weight loss 
may be primarily through the hypothalamus, affecting both 
the sense of satiety mediated in the ventromedial hypothala-
mus and hunger recognition mediated in the lateral hypo-
thalamus. Decreased gastric motility has also been proposed 
as a contributing mechanism, controlled in the dorsomedial 
Association Between Topiramate and Zonisamide Use During Pregnancy and Low Birth Weight.
Hernández-Díaz S, Mittendorf R, Smith CR, Hauser WA, Yerby M, Holmes LB; for the North American Antiepileptic Drug 
Pregnancy Registry. Obstet Gynecol 2014;123:21–28.
The recent article from the North American Antiepileptic Drug Pregnancy Registry (NAAEDPR) presents data showing 
that babies exposed in utero to topiramate (TPM) and zonisamide (ZNS) have a significantly lower birth weight and 
shorter length than babies exposed to lamotrigine (LTG) or a control group. This difference, of a mean of 200 grams in 
weight and 1 cm in length, when controlled for gestational age, contributed to a higher than expected proportion of 
babies who were small for gestational age (SGA) occurring in the TPM and ZNS groups.
Topiramate, Zonisamide and Small For Gestational Age: 
Maternal Factors, Timing of Exposure and Baby Fat
200
TPM, ZNS, and SGA
hypothalamic nucleus. One recent report (10) supports this hy-
pothesis; in a study of 40 migraine patients treated with topi-
ramate 100 mg/day for three months, a significant reduction in 
body fat occurred, without a change in the resting metabolic 
rate (RMR), pointing toward a hypothalamic mechanism .
There was no dose effect found, but there was a profound 
timing effect. The proportion of SGA in offspring whose 
mothers stopped topiramate monotherapy before the third 
trimester was quite low at 7.3%, while for those who contin-
ued it throughout the third trimester, the rate was highest at 
19.6%. This difference was not significant, likely due to small 
numbers (not given), but the trend is interesting, as is the 
trend polytherapy on increasing the rates of SGA especially 
with topiramate use.
The third trimester is the period of gestation when most 
fetal body fat is deposited. At 20-weeks gestation, fat com-
prises 0.5% of the fetal body, after which the amount increases, 
reaching 7.8% at the 34-weeks gestation, and 16% before birth. 
Nearly 500 g of fetal body fat are acquired in the last trimester 
of pregnancy and during the last month of intrauterine life the 
fetus gains as much as 14 g of fat per day (11). Does topiramate 
minimize fetal body fat deposition, as suggested by timing of an 
adverse effect in correlation with fetal growth patterns?
This information, while incomplete and difficult to explain 
since fetuses don’t eat and we do not have information on ma-
ternal weight gain, deserves consideration when counseling 
women with epilepsy and migraine who take these medica-
tions. These mothers may need to consciously override their 
hypothalamically-mediated behavior and eat more!
by Cynthia L. Harden, M.D.
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